THRD Stock Overview
A biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Third Harmonic Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.38 |
| 52 Week High | US$16.94 |
| 52 Week Low | US$8.08 |
| Beta | 2.66 |
| 1 Month Change | -18.65% |
| 3 Month Change | -20.40% |
| 1 Year Change | -5.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.26% |
Recent News & Updates
Third Harmonic Bio (NASDAQ:THRD) Is In A Good Position To Deliver On Growth Plans
Nov 16
Companies Like Third Harmonic Bio (NASDAQ:THRD) Can Afford To Invest In Growth
Aug 03Recent updates
Third Harmonic Bio (NASDAQ:THRD) Is In A Good Position To Deliver On Growth Plans
Nov 16Companies Like Third Harmonic Bio (NASDAQ:THRD) Can Afford To Invest In Growth
Aug 03Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation
Apr 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
Sep 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
May 02We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate
Dec 16Shareholder Returns
| THRD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.9% | -1.9% | -1.1% |
| 1Y | -5.4% | 6.5% | 22.4% |
Return vs Industry: THRD underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: THRD underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| THRD volatility | |
|---|---|
| THRD Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THRD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: THRD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 51 | Natalie Holles | www.thirdharmonicbio.com |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions.
Third Harmonic Bio, Inc. Fundamentals Summary
| THRD fundamental statistics | |
|---|---|
| Market cap | US$462.30m |
| Earnings (TTM) | -US$39.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.9x
P/E RatioIs THRD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THRD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$39.20m |
| Earnings | -US$39.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did THRD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 09:05 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Third Harmonic Bio, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akash Tewari | Jefferies LLC |
| Michael Ulz | Morgan Stanley |
| Laura Prendergast | Raymond James & Associates |